Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer

Yoshitaka Oyamada, Hideo Watanabe, Koichi Fukunaga, Hidetoshi Nakamura, Koichiro Asano, Naoki Hasegawa, Kazuhiro Yamaguchi

Research output: Contribution to journalArticle

Abstract

We retrospectively analyzed the effects of dosages of docetaxel (DOC) in combination chemotherapy with carboplatin (CBDCA) against advanced non-small cell lung cancer (NSCLC). Twenty-three cases of previously untreated NSCLC (stage III and IV, performance status: 0-1) that were pathologically or cytologically confirmed were divided into 2 groups (DOC-60, DOC-70) based on their received DOC doses (60 and 70 mg/m2, respectively). Both groups had similar patient characteristics and received similar treatment except for their DOC doses. Although not statistically significant, the response rates after the completion of whole cycles of the treatment (mean: 4 cycles) were 18.2% in DOC-60 and 41.6% in DOC-70. Leukocytopenia, neutropenia and anemia were observed similarly in both groups. However, while thrombocytopenia was not observed in DOC-70, it was found in 36.4% of the cases in DOC-60. In combination chemotherapy with carboplatin against advanced NSCLC, the use of DOC at 70 mg/m2 was rather protective against thrombocytopenia, keeping the response equivalent or possibly superior to that obtained in the patients treated with DOC at 60 mg/m2.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number12
Publication statusPublished - 2003 Nov

Fingerprint

docetaxel
Carboplatin
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer. / Oyamada, Yoshitaka; Watanabe, Hideo; Fukunaga, Koichi; Nakamura, Hidetoshi; Asano, Koichiro; Hasegawa, Naoki; Yamaguchi, Kazuhiro.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 12, 11.2003, p. 1917-1922.

Research output: Contribution to journalArticle

Oyamada, Yoshitaka ; Watanabe, Hideo ; Fukunaga, Koichi ; Nakamura, Hidetoshi ; Asano, Koichiro ; Hasegawa, Naoki ; Yamaguchi, Kazuhiro. / Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 12. pp. 1917-1922.
@article{644f9a002e514132af4f133c585cd684,
title = "Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer",
abstract = "We retrospectively analyzed the effects of dosages of docetaxel (DOC) in combination chemotherapy with carboplatin (CBDCA) against advanced non-small cell lung cancer (NSCLC). Twenty-three cases of previously untreated NSCLC (stage III and IV, performance status: 0-1) that were pathologically or cytologically confirmed were divided into 2 groups (DOC-60, DOC-70) based on their received DOC doses (60 and 70 mg/m2, respectively). Both groups had similar patient characteristics and received similar treatment except for their DOC doses. Although not statistically significant, the response rates after the completion of whole cycles of the treatment (mean: 4 cycles) were 18.2{\%} in DOC-60 and 41.6{\%} in DOC-70. Leukocytopenia, neutropenia and anemia were observed similarly in both groups. However, while thrombocytopenia was not observed in DOC-70, it was found in 36.4{\%} of the cases in DOC-60. In combination chemotherapy with carboplatin against advanced NSCLC, the use of DOC at 70 mg/m2 was rather protective against thrombocytopenia, keeping the response equivalent or possibly superior to that obtained in the patients treated with DOC at 60 mg/m2.",
author = "Yoshitaka Oyamada and Hideo Watanabe and Koichi Fukunaga and Hidetoshi Nakamura and Koichiro Asano and Naoki Hasegawa and Kazuhiro Yamaguchi",
year = "2003",
month = "11",
language = "English",
volume = "30",
pages = "1917--1922",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer

AU - Oyamada, Yoshitaka

AU - Watanabe, Hideo

AU - Fukunaga, Koichi

AU - Nakamura, Hidetoshi

AU - Asano, Koichiro

AU - Hasegawa, Naoki

AU - Yamaguchi, Kazuhiro

PY - 2003/11

Y1 - 2003/11

N2 - We retrospectively analyzed the effects of dosages of docetaxel (DOC) in combination chemotherapy with carboplatin (CBDCA) against advanced non-small cell lung cancer (NSCLC). Twenty-three cases of previously untreated NSCLC (stage III and IV, performance status: 0-1) that were pathologically or cytologically confirmed were divided into 2 groups (DOC-60, DOC-70) based on their received DOC doses (60 and 70 mg/m2, respectively). Both groups had similar patient characteristics and received similar treatment except for their DOC doses. Although not statistically significant, the response rates after the completion of whole cycles of the treatment (mean: 4 cycles) were 18.2% in DOC-60 and 41.6% in DOC-70. Leukocytopenia, neutropenia and anemia were observed similarly in both groups. However, while thrombocytopenia was not observed in DOC-70, it was found in 36.4% of the cases in DOC-60. In combination chemotherapy with carboplatin against advanced NSCLC, the use of DOC at 70 mg/m2 was rather protective against thrombocytopenia, keeping the response equivalent or possibly superior to that obtained in the patients treated with DOC at 60 mg/m2.

AB - We retrospectively analyzed the effects of dosages of docetaxel (DOC) in combination chemotherapy with carboplatin (CBDCA) against advanced non-small cell lung cancer (NSCLC). Twenty-three cases of previously untreated NSCLC (stage III and IV, performance status: 0-1) that were pathologically or cytologically confirmed were divided into 2 groups (DOC-60, DOC-70) based on their received DOC doses (60 and 70 mg/m2, respectively). Both groups had similar patient characteristics and received similar treatment except for their DOC doses. Although not statistically significant, the response rates after the completion of whole cycles of the treatment (mean: 4 cycles) were 18.2% in DOC-60 and 41.6% in DOC-70. Leukocytopenia, neutropenia and anemia were observed similarly in both groups. However, while thrombocytopenia was not observed in DOC-70, it was found in 36.4% of the cases in DOC-60. In combination chemotherapy with carboplatin against advanced NSCLC, the use of DOC at 70 mg/m2 was rather protective against thrombocytopenia, keeping the response equivalent or possibly superior to that obtained in the patients treated with DOC at 60 mg/m2.

UR - http://www.scopus.com/inward/record.url?scp=0642364478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642364478&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 1917

EP - 1922

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -